[go: up one dir, main page]

WO2003041645A3 - Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques - Google Patents

Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques Download PDF

Info

Publication number
WO2003041645A3
WO2003041645A3 PCT/US2002/035957 US0235957W WO03041645A3 WO 2003041645 A3 WO2003041645 A3 WO 2003041645A3 US 0235957 W US0235957 W US 0235957W WO 03041645 A3 WO03041645 A3 WO 03041645A3
Authority
WO
WIPO (PCT)
Prior art keywords
tumors
human patient
vaccinating
methods
metastatic tumors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/035957
Other languages
English (en)
Other versions
WO2003041645A2 (fr
Inventor
Ning Y Yu
Jian-Min Lin
Robert J Tressler
Richard E Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Priority to EP02778802A priority Critical patent/EP1453468A4/fr
Priority to AU2002340439A priority patent/AU2002340439A1/en
Publication of WO2003041645A2 publication Critical patent/WO2003041645A2/fr
Publication of WO2003041645A3 publication Critical patent/WO2003041645A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Méthodes permettant de prévenir ou d'inhiber les tumeurs métastatiques chez un patient humain immunocompétent. Spécifiquement, les méthodes selon la présente invention consistent à identifier une ou plusieurs tumeurs solides chez un patient humain, lesdites tumeurs étant accessibles par des techniques d'injection. Une première dose d'une composition pharmaceutique est administrée à la tumeur ou aux tumeurs solides accessibles, en quantité efficace pour déclencher une réponse immunitaire à la tumeur ou aux tumeurs. La réponse immunitaire déclenchée par les méthodes selon la présente invention peut également présenter une mémoire immunologique.
PCT/US2002/035957 2001-11-09 2002-11-08 Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques Ceased WO2003041645A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP02778802A EP1453468A4 (fr) 2001-11-09 2002-11-08 Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques
AU2002340439A AU2002340439A1 (en) 2001-11-09 2002-11-08 Method of vaccinating a human patient to prevent metastatic tumors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33798401P 2001-11-09 2001-11-09
US60/337,984 2001-11-09

Publications (2)

Publication Number Publication Date
WO2003041645A2 WO2003041645A2 (fr) 2003-05-22
WO2003041645A3 true WO2003041645A3 (fr) 2003-07-24

Family

ID=23322894

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/035957 Ceased WO2003041645A2 (fr) 2001-11-09 2002-11-08 Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques

Country Status (3)

Country Link
EP (1) EP1453468A4 (fr)
AU (1) AU2002340439A1 (fr)
WO (1) WO2003041645A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN113993522A (zh) 2019-04-17 2022-01-28 指南针探路者有限公司 用赛洛西宾治疗焦虑障碍、头痛病症和进食障碍的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09507233A (ja) * 1993-12-29 1997-07-22 マトリクス ファーマスーティカル，インコーポレイティド 細胞増殖性疾患に罹る宿主の治療方法及び治療のための組成物
US5478556A (en) * 1994-02-28 1995-12-26 Elliott; Robert L. Vaccination of cancer patients using tumor-associated antigens mixed with interleukin-2 and granulocyte-macrophage colony stimulating factor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
GRIMM E.A. ET AL.: "Unexprected cytokines in serum of malignant melanoma patients during sequential biochemotherapy", CLIN. CANCER RES., vol. 6, no. 10, October 2000 (2000-10-01), pages 3895 - 3903, XP002963858 *
MUGINOVA S.: "Inhibition of peroxidase, trypsin and alpha-chymotrypsin by platinum(II) and platinum(IV) complexes", BIOCHEMISTRY (MOSC), vol. 64, no. 4, April 1999 (1999-04-01), pages 399 - 404 *
PAVIA M.B.: "Laser and cisplatinum for treatment of human squamous cell carcinoma", LARYNGOSCOPE, vol. 108, no. 9, September 1998 (1998-09-01), pages 1269 - 1276 *

Also Published As

Publication number Publication date
EP1453468A4 (fr) 2005-11-23
EP1453468A2 (fr) 2004-09-08
WO2003041645A2 (fr) 2003-05-22
AU2002340439A1 (en) 2003-05-26

Similar Documents

Publication Publication Date Title
WO2005062972A3 (fr) Traitement du cancer au moyen de nouveaux anticorps monoclonaux anti-il 13
EP2022800A3 (fr) Compositions utilisés dans la thérapie et le diagnostic du cancer des ovaires
WO2000036107A3 (fr) Compositions et procedes destines a la therapie et au diagnostic du cancer de l"ovaire
EP2116262A3 (fr) Analyse de détection génique permettant d'améliorer la probabilité d'une réponse efficace à une thérapie du cancer basée sur un antagoniste d'ErbB
TR199802676A3 (tr) Tümörlerin, tümörle ilgili hastaliklarin ve kaseksinin tedavisi ve önlenmesi için yöntem.
WO2000062800A3 (fr) Vaccins
WO2003030934A3 (fr) Formulations cpg et procedes y relatifs
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
NO20101067L (no) Hydroksymatairesinol i forhindring av kreft
CA2396865A1 (fr) Inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer du sein
IL201889A (en) Medication for the treatment of vaccine-related disorders containing antibodies that specifically recognize the nk 1.1 antigen or cd56 antigen expressed by nk t cells
EP1391200A4 (fr) Preparations de medicaments
IS7691A (is) Lyfjasamsetningar til að meðhöndla æxli
WO2005007673A3 (fr) Peptides immunogenes
WO1998045328A3 (fr) Compositions therapeutiques et diagnostiques du carcinome mammaire et methodes afferentes
WO2001018046A3 (fr) Sequences de tumeurs ovariennes et procedes d'utilisation correspondants
WO2001014395A3 (fr) Nouveaux glycoconjuges et acides glycoamino leurs intermediaires et leurs utilisations
WO2003041645A3 (fr) Methode de vaccination d'un patient humain pour prevenir les tumeurs metastatiques
EE200300129A (et) Distamütsiini alfa-halogenoakrüloüülderivaadi kasutamine
WO2001090152A3 (fr) Compositions et procedes pour la therapie et le diagnostic du cancer du sein
WO2003093298A3 (fr) Peptides immunogenes
WO2000052045A3 (fr) Peptides immunogenes derives de mage-3 presentes par le complexe majeur d'histocompatibilte (mch) de categorie ii et utilisations associees
DE50110274D1 (de) Arzneimittel zur immuntherapie maligner tumoren
WO2002045657A3 (fr) Antigene de la tumeur de l'ovaire et ses utilisations

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002778802

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002778802

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002778802

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP